摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-溴乙氧基)丙烷 | 54149-16-5

中文名称
2-(2-溴乙氧基)丙烷
中文别名
异丙基-2-溴乙醚
英文名称
2-isopropyloxyethyl bromide
英文别名
2-bromoethyl isopropyl ether;2-isopropoxy ethyl bromide;2-(2-bromoethoxy)propane;1-bromo-2-isopropoxyethane;1-bromo-2-isopropoxy-ethane;(2-Brom-aethyl)-isopropyl-aether
2-(2-溴乙氧基)丙烷化学式
CAS
54149-16-5
化学式
C5H11BrO
mdl
MFCD07700570
分子量
167.046
InChiKey
KYKUZTBLYLKPIT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    139.9-140.2 °C(Press: 743 Torr)
  • 密度:
    1.2609 g/cm3

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    7
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2909199090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    存储条件:室温、密封、干燥

SDS

SDS:bce62a53f1ad9696cc45dd630b599341
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-(2-Bromoethoxy)propane
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-(2-Bromoethoxy)propane
CAS number: 54149-16-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H11BrO
Molecular weight: 167.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    2-(2-溴乙氧基)丙烷硫脲 、 sodium hydroxide 作用下, 以 乙醇 为溶剂, 反应 26.0h, 以82%的产率得到2-异丙氧基乙硫醇
    参考文献:
    名称:
    带有悬垂醚部分的硫醇盐桥接的二钌配合物在分子二氢的氧化中的催化活性
    摘要:
    已发现带有侧基醚的硫醇盐桥接的二钌络合物可作为有效的催化剂,将分子中的二氢氧化为水中的质子和电子。络合物中的侧基醚部分在促进质子在金属中心和外部质子受体之间转移方面起着重要作用。
    DOI:
    10.1002/chem.201604974
  • 作为产物:
    描述:
    参考文献:
    名称:
    带有悬垂醚部分的硫醇盐桥接的二钌配合物在分子二氢的氧化中的催化活性
    摘要:
    已发现带有侧基醚的硫醇盐桥接的二钌络合物可作为有效的催化剂,将分子中的二氢氧化为水中的质子和电子。络合物中的侧基醚部分在促进质子在金属中心和外部质子受体之间转移方面起着重要作用。
    DOI:
    10.1002/chem.201604974
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINE EN TANT QU'INHIBITEURS DE LA KINASE RET
    申请人:ANDREWS STEVEN W
    公开号:WO2018071447A1
    公开(公告)日:2018-04-19
    Provided herein are compounds of the Formula I and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    本文件提供了公式I的化合物以及立体异构体和药用可接受的盐或溶剂化物,其中A、B、X1、X2、X3、X4、环D和E具有说明书中给出的含义,它们是RET激酶的抑制剂,可用于治疗和预防可通过RET激酶抑制剂治疗的疾病,包括与RET相关疾病和失调。
  • [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
    申请人:ANDREWS STEVEN W
    公开号:WO2018071454A1
    公开(公告)日:2018-04-19
    Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    本文提供了Formula I的化合物:(I)或其药用可接受的盐或溶剂,其中A、B、X1、X2、X3、X4、环D、E、Ra、Rb、n和m的含义如规范中所述,它们是RET激酶的抑制剂,并且在治疗和预防可以用RET激酶抑制剂治疗的疾病中非常有用,包括与RET相关的疾病和紊乱。
  • HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR
    申请人:BAYER PHARMA AKTIENGESELLSCHAFT
    公开号:US20180065981A1
    公开(公告)日:2018-03-08
    The present application relates to novel thieno[2,3-d]pyrimidine-2,4-dione (“thienouracil”) derivatives bearing a particular type of (azaheterocyclyl)methyl substituent, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of pulmonary and cardiovascular disorders and of cancer.
    本申请涉及具有特定类型的(氮杂杂环基)甲基取代基的新型噻吩并[2,3-d]嘧啶-2,4-二酮(“噻吩尿嘧啶”)衍生物,以及其制备方法,单独或组合用于治疗和/或预防疾病,以及用于生产用于治疗和/或预防疾病的药物,特别是用于治疗和/或预防肺部和心血管疾病以及癌症的用途。
  • FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS
    申请人:Novartis AG
    公开号:US20180312507A1
    公开(公告)日:2018-11-01
    The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.
    这项发明提供了如下所述的化合物的化学式(I),以及药用盐、含有这些化合物的药物组合物,以及使用这些化合物、盐和组合物治疗病毒感染,特别是由乙型肝炎病毒引起的感染,并减少与HBV相关的严重病情发生的方法。
  • Pyranouidole Derivatives and the Use Thereof for the Treatment of Hepatitis C Virus Infection or Disease
    申请人:Condon M. Stephen
    公开号:US20070219212A1
    公开(公告)日:2007-09-20
    The invention is directed to novel pyranoindole derivatives and analogs as well as compositions containing the same and to the use thereof for the treatment, prevention or inhibition of viral infections and associated diseases caused by the Hepatitis C virus.
    这项发明涉及新型吡喃吲哚衍生物和类似物,以及含有这些物质的组合物,以及将其用于治疗、预防或抑制由丙型肝炎病毒引起的病毒感染和相关疾病的用途。
查看更多